Isoptin Retard

Verapamil Hydrochloride, the active ingredient in Isoptin Retard, is a calcium channel blocker presented as an oral tablet for systemic use. It is employed to manage high blood pressure, chest pain from angina, and certain cardiac rhythm disturbances in adult patients.

GNH USA supplies Isoptin Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isoptin Retard is a calcium channel blocker indicated for several cardiovascular conditions. - Hypertension: lowers elevated blood pressure by relaxing vascular smooth muscle. - Angina pectoris: reduces myocardial oxygen demand and improves coronary blood flow, relieving chest pain. - Cardiac arrhythmias: slows atrioventricular nodal conduction to control abnormal heart rhythms such as supraventricular tachycardia.

Adverse reactions may occur with verapamil therapy and should be monitored.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Constipation: reduced bowel motility. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Bradycardia: markedly slowed heart rate. - Hypotension: significant drop in blood pressure. - AV block: impaired atrioventricular conduction. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety measures. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Cardiac function assessment: evaluate for existing heart failure or conduction disorders. - Concomitant beta‑blocker use: assess risk of additive bradycardia. - Hepatic impairment: adjust therapy if severe liver disease is present. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Verapamil may interact with a range of medicines; awareness helps prevent adverse events.

Major Interactions (Avoid): - Beta‑blockers: combined use can cause profound bradycardia or AV block. - Digoxin: increased serum levels may lead to toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): elevate verapamil concentrations. - Diltiazem: additive effects on cardiac conduction and contractility.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect. - Simvastatin or other statins metabolized by CYP3A4: monitor for muscle toxicity. - Rifampin (CYP3A4 inducer): may reduce verapamil efficacy. - Lithium: monitor serum lithium levels for potential increase.